Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.59), $0.08 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Iran Says Hormuz To Close, Citing Ceasefire Violation- Tasnim
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group